356 related articles for article (PubMed ID: 34393221)
21. Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Sun G; Zhang X; Liang J; Pan X; Zhu S; Liu Z; Armstrong CM; Chen J; Lin W; Liao B; Lin T; Huang R; Zhang M; Zheng L; Yin X; Nie L; Shen P; Zhao J; Zhang H; Dai J; Shen Y; Li Z; Liu J; Chen J; Liu J; Wang Z; Zhu X; Ni Y; Qin D; Yang L; Chen Y; Wei Q; Li X; Zhou Q; Huang H; Yao J; Chen N; Zeng H
Clin Cancer Res; 2021 Mar; 27(6):1734-1743. PubMed ID: 33414138
[TBL] [Abstract][Full Text] [Related]
22. Utilization of a TFE3 break-apart FISH assay in a renal tumor consultation service.
Green WM; Yonescu R; Morsberger L; Morris K; Netto GJ; Epstein JI; Illei PB; Allaf M; Ladanyi M; Griffin CA; Argani P
Am J Surg Pathol; 2013 Aug; 37(8):1150-63. PubMed ID: 23715164
[TBL] [Abstract][Full Text] [Related]
23. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
[TBL] [Abstract][Full Text] [Related]
24. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopatholigic features of renal cell carcinoma associated with chromosome X inversion harboring gene fusions involving TFE3].
Zhao YN; Wang XT; Xia QY; Wang GP; Sun SY; Zhao LF; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):574-579. PubMed ID: 30107660
[No Abstract] [Full Text] [Related]
26. [FH-deficient renal cell carcinoma expands the spectrum of renal papillary tumors].
Rupp N; Moch H
Pathologe; 2021 Nov; 42(6):560-564. PubMed ID: 34448900
[TBL] [Abstract][Full Text] [Related]
27. Fumarate hydratase deficient renal cell carcinoma and fumarate hydratase deficient-like renal cell carcinoma: Morphologic comparative study of 23 genetically tested cases.
Pivovarčíková K; Martínek P; Trpkov K; Alaghehbandan R; Magi-Galluzzi C; Mundo EC; Berney D; Suster S; Gill A; Rychlý B; Michalová K; Pitra T; Hora M; Michal M; Hes O
Cesk Patol; 2019; 55(4):244-249. PubMed ID: 31842557
[TBL] [Abstract][Full Text] [Related]
28. Approach for reclassification of collecting duct carcinoma and comparative histopathological analysis with SMARCB1/INI1-deficient renal cell carcinoma and fumarate hydratase-deficient renal cell carcinoma.
Kiyozawa D; Kohashi K; Takamatsu D; Iwasaki T; Shibata D; Tomonaga T; Tateishi Y; Eto M; Kinjo M; Nishiyama K; Taguchi K; Oshiro Y; Kuboyama Y; Furuya M; Oda Y
Hum Pathol; 2022 Jun; 124():36-44. PubMed ID: 35306021
[TBL] [Abstract][Full Text] [Related]
29. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morphologically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma.
Smith SC; Sirohi D; Ohe C; McHugh JB; Hornick JL; Kalariya J; Karia S; Snape K; Hodgson SV; Cani AK; Hovelson D; Luthringer DJ; Martignoni G; Chen YB; Tomlins SA; Mehra R; Amin MB
Histopathology; 2017 Jul; 71(1):42-52. PubMed ID: 28165631
[TBL] [Abstract][Full Text] [Related]
30. Molecular-genetic analysis is essential for accurate classification of renal carcinoma resembling Xp11.2 translocation carcinoma.
Hayes M; Peckova K; Martinek P; Hora M; Kalusova K; Straka L; Daum O; Kokoskova B; Rotterova P; Pivovarčikova K; Branzovsky J; Dubova M; Vesela P; Michal M; Hes O
Virchows Arch; 2015 Mar; 466(3):313-22. PubMed ID: 25544614
[TBL] [Abstract][Full Text] [Related]
31. "Mucin"-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases.
Pivovarcikova K; Peckova K; Martinek P; Montiel DP; Kalusova K; Pitra T; Hora M; Skenderi F; Ulamec M; Daum O; Rotterova P; Ondic O; Dubova M; Curik R; Dunatov A; Svoboda T; Michal M; Hes O
Virchows Arch; 2016 Jul; 469(1):71-80. PubMed ID: 27072821
[TBL] [Abstract][Full Text] [Related]
32. A Clinicopathological and Molecular Analysis of Fumarate Hydratase (FH)-deficient Renal Cell Carcinomas with Heterogeneous Loss of FH Expression.
Anderson WJ; Tsai HK; Sholl LM; Hirsch MS
Int J Surg Pathol; 2022 Sep; 30(6):606-615. PubMed ID: 35048731
[No Abstract] [Full Text] [Related]
33. Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening.
Siegler L; Erber R; Burghaus S; Brodkorb T; Wachter D; Wilkinson N; Bolton J; Stringfellow H; Haller F; Beckmann MW; Hartmann A; Agaimy A
Virchows Arch; 2018 May; 472(5):789-796. PubMed ID: 29332133
[TBL] [Abstract][Full Text] [Related]
34. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
35. [Acquired cystic kidney disease-associated renal cell carcinoma: a clinicopathologic study of three cases].
Zhang W; Xu LL; Yu WJ; Wang Q; Jiang YX; Liu Y; Li YJ
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):366-371. PubMed ID: 29783804
[No Abstract] [Full Text] [Related]
36. Fumarate Hydratase-deficient Uterine Leiomyomas Occur in Both the Syndromic and Sporadic Settings.
Harrison WJ; Andrici J; Maclean F; Madadi-Ghahan R; Farzin M; Sioson L; Toon CW; Clarkson A; Watson N; Pickett J; Field M; Crook A; Tucker K; Goodwin A; Anderson L; Srinivasan B; Grossmann P; Martinek P; Ondič O; Hes O; Trpkov K; Clifton-Bligh RJ; Dwight T; Gill AJ
Am J Surg Pathol; 2016 May; 40(5):599-607. PubMed ID: 26574848
[TBL] [Abstract][Full Text] [Related]
37. Immunohistochemistry for 2-Succinocysteine (2SC) and Fumarate Hydratase (FH) in Cutaneous Leiomyomas May Aid in Identification of Patients With HLRCC (Hereditary Leiomyomatosis and Renal Cell Carcinoma Syndrome).
Buelow B; Cohen J; Nagymanyoki Z; Frizzell N; Joseph NM; McCalmont T; Garg K
Am J Surg Pathol; 2016 Jul; 40(7):982-8. PubMed ID: 26945337
[TBL] [Abstract][Full Text] [Related]
38. A patient with very early onset FH-deficient renal cell carcinoma diagnosed at age seven.
Taniguchi R; Muramatsu H; Okuno Y; Yoshida T; Wakamatsu M; Hamada M; Shirota C; Sumida W; Hinoki A; Tainaka T; Gotoh Y; Tsuzuki T; Tanaka Y; Kojima S; Uchida H; Takahashi Y
Fam Cancer; 2022 Jul; 21(3):337-341. PubMed ID: 34156580
[TBL] [Abstract][Full Text] [Related]
39. Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female.
Wyvekens N; Anderson WJ; Kim YX; Carter M; Hirsch MS
Int J Surg Pathol; 2022 Apr; 30(2):184-189. PubMed ID: 34180725
[TBL] [Abstract][Full Text] [Related]
40. Low-grade Oncocytic Fumarate Hydratase-deficient Renal Cell Carcinoma: An Update on Biologic Potential, Morphologic Spectrum, and Differential Diagnosis With Other Low-grade Oncocytic Tumors.
Hamza A; Sirohi D; Smith SC; Amin MB
Adv Anat Pathol; 2021 Nov; 28(6):396-407. PubMed ID: 34561376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
